SOAT1 and myeloproliferative disorder: JAK inhibitors such as ruxolitinib and fedratinib can control the symptoms of MF, in particular splenomegaly, but MPN cells are not cleared by these drugs, perhaps due to the inherent resistance of stem cell populations [139] or by persistent cross activation of JAK-STAT signaling [140].